Ann: BARD1 Demonstrates Feasibility of SubB2M-Based IHC Test, page-45

if for example BD1 licensed the use of AI tech from LBT, a module could feasibly be approved in months & then on licensed to VHT (breast density software provider covering 32% of the US market), the roll out to the majority of US women could be quite seamless - and if they are able to improve the histopatholgy accuracy to 100% (from between 50-75%) this is huge huge. all of the LBT modules work by identifying positives and having a human pathologist review. the academic journals discussing the mis classification on histopatholgy breast samples recommend samples are reviews always by 2 pathologists however - this is limited by availability of pathologist time.